Calls to expand access to oral antiviral drugs for COVID-19

“I really do think those tablets helped us a lot, because we did not have [any symptoms] after, ”McWilliam said.

The call to widen access to the COVID-19 medications follows the Victorian government’s announcement that it will scale back its mass testing and vaccination sites within a week, as GPs and pharmacies deliver more than 70 per cent of vaccinations and rapid antigen tests are widely used .

‘I really do think those tablets helped us a lot.’

Jeanette McWilliam

However, emergency wards around the country are still struggling to cope with the influx of patients presenting with COVID-19 and the flu, prompting the federal government to push for a greater uptake of antiviral medications to ease the pressure on the system.

Federal Health Minister Mark Butler wants eligible people who test positive for COVID-19 to receive a text message from the Health Department with information about the antiviral drugs that are available.

Butler said the Pharmaceutical Benefits Advisory Committee (PBAC) would continue monitoring the eligibility criteria for access to the drugs, which are currently available to people over 18 who are immunocompromised and at risk of developing severe disease or high-risk adults over 65.


“The PBAC may recommend changes to the eligibility criteria as needed, considering new evidence for the effectiveness and safety of these antivirals in other patient groups as well as the evolving epidemiology of COVID-19,” Butler said.

“Any expansion of eligibility will be considered by the PBAC at its next meeting, in early July, which will consider the potential benefits and harms of these medications.”

Robert Booy, an infectious diseases pediatrician at the University of Sydney, said broadening access to safe and effective antiviral medication to help keep people out of hospital was a “worthwhile proposition”.

“These people will be getting their viral load reduced, so the amount of virus in their body is reduced by the antiviral. That may – it’s not proven – but that may have an impact on lessening transmission. ”


University of Queensland infectious diseases physician Paul Griffin said he did not think expanding eligibility would exhaust the country’s antiviral supply. “I think we’re a long way off that right now,” he said.

Australian National University infectious disease expert Peter Collignon said a cost-benefit analysis should be done to avoid unnecessary expenditure, while the risks of side effects and drug interactions for some patients must be considered.

“There are probably a lot more people who would benefit from the antivirals, particularly those over the age of 65 who do not know about it and are not seeking medical advice fast enough.”

Royal Australian College of General Practitioners’ Victorian council chair, Anita Munoz, said she also supported expanding the criteria to more vulnerable people, as long as the net was not cast too wide and did not overwhelm GPs already facing unprecedented demand.

“We want high-risk individuals to use the medications,” she said. “What we do not want is to frustrate both GPs and patients by having low-risk patients seek out appointments, only to be told they are not the target group.”

The Morning Edition newsletter is our guide to the day’s most important and interesting stories, analysis and insights. Sign up here.

Leave a Comment